利拉鲁肽对2型糖尿病合并冠心病患者心脏舒张功能的影响

Effects of Liraglutide on Diastolic Function Parameters in Patients with Type 2 Diabetes and Coronary Heart Disease

摘要: 目的：探讨利拉鲁肽对2型糖尿病合并冠心病患者心脏舒张功能的影响。方法：回顾性分析2020年6月至2022年6月收治的2型糖尿病合并冠心病患者86例，根据治疗方法将患者分为胰岛素组和利拉鲁肽组，各43例。在常规治疗基础上，胰岛素组应用盐酸二甲双胍联合甘精胰岛素治疗，利拉鲁肽组应用二甲双胍联合利拉鲁肽治疗，利用二维超声心动图的组织多普勒成像技术评估两组患者心脏舒张功能参数。结果：与胰岛素相比，利拉鲁肽能够显著降低患者平均e’和侧壁e’速度(分别为−0.57 cm/s (−1.05~−0.08)和−0.74 cm/s (−1.22~−0.10), p < 0.05)。并能够升高心率(6.06 (0.74~10.36), p < 0.05)。结论：利拉鲁肽可提高2型糖尿病合并冠心病患者的心率，影响心脏舒张功能。

Abstract: Objective: To investigate the effect of liraglutide on diastolic function in patients with type 2 diabe-tes mellitus and coronary heart disease. Methods: A total of 86 patients with type 2 diabetes melli-tus complicated with coronary heart disease admitted from June 2020 to June 2022 were selected. According to the treatment method, the patients were divided into insulin group and liraglutide group, with 43 cases in each group. On the basis of conventional treatment, the insulin group was treated with metformin hydrochloride combined with insulin glargine, and the liraglutide group was treated with metformin combined with liraglutide. The diastolic function parameters of the two groups were evaluated by tissue Doppler imaging of two-dimensional echocardiography. Results: Compared with the insulin, liraglutide significantly reduced the mean e’ and lateral e’ velocity (−0.57 cm/s (−1.05~−0.08) and -0.74 cm/s (−1.22~−0.10), respectively, p < 0.05). It also increased heart rate (6.06 (0.74~10.36), p < 0.05). Conclusions: Liraglutide can increase heart rate and affect cardiac diastolic function in patients with type 2 diabetes mellitus and coronary heart disease.